DOSAGE INDEX / SINGLE
Cerebrolysin
Research, reported schedules and supply planning.
Compare CARS, CASTA and CERE-LYSE findings, distinguishing early recovery signals, primary endpoints, rehabilitation context and preparation identity.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 20–32 mg total per day
- Frequency
- Daily, with divided administrations in the source
- Cycle / observation period
- 8–12 weeks; source also mentions 16 weeks
- Route / research model
- Subcutaneous
The source uses a 60 mg powder example. This is not interchangeable with the manufactured solution or its clinical routes and concentrations.
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 60 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- CARS compared Cerebrolysin with placebo alongside a standardized rehabilitation program after ischemic stroke. The primary endpoint was the Action Research Arm Test at day 90. The study reported better arm-function and combined global outcomes with Cerebrolysin. The authors described the study as exploratory and called for a larger confirmatory trial. [1]
- CASTA enrolled 1,070 patients with acute ischemic stroke and compared Cerebrolysin with placebo in addition to background treatment. The confirmatory combined endpoint did not show a significant difference. A post hoc analysis in patients with more severe strokes suggested a favorable trend, but that exploratory result was not the successful primary outcome of the overall trial. [2]
- A trial in 119 patients compared Cerebrolysin with placebo after alteplase treatment. It stopped after an interim analysis showed no benefit on its primary day-90 modified Rankin Scale outcome. Some earlier neurological responder measures favored Cerebrolysin, and reported adverse events did not differ between groups. [3]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 11 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.
- CARS original trial
- CASTA original trial
- Lang and colleagues, original study
- Original endothelial-cell study
- Alzheimer’s Drug Discovery FoundationFurther reading · Listed in reference bibliography.
- Zhang et al., Med Sci Monit (PMC)Further reading · Listed in reference bibliography.
- Kurkin et al., PLOS OneFurther reading · Listed in reference bibliography.
- Espinoza et al., Behav Brain Res (PubMed)Further reading · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
- WHOFurther reading · Listed in reference bibliography.
- NCBI BookshelfFurther reading · Listed in reference bibliography.
- Subcutaneous Drug Delivery Review (PMC)Further reading · Listed in reference bibliography.
- Cognitive Frailty & Cerebrolysin Review (PMC)Further reading · Listed in reference bibliography.
- Neurotrophic Factors & Neurodegeneration (PMC)Further reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.